What HPLC vs Mass Spec Actually Tells Me About Purity

The year was 2021, and my bloodwork came back looking like a dumpster fire. My doctor, bless her heart, suggested I eat more kale. I, being a software engineer with a penchant for data and a deep-seated distrust of generic advice, decided to dive headfirst into the rabbit hole of human optimization. That’s how I ended up spending the last few years elbow-deep in research-peptide pharmacology, meticulously tracking everything, and trying to make sense of the wild west that is the peptide market. I'm not a doctor, just a guy who reads a lot of studies and tests a lot of theories on himself (and sometimes, on the brave souls who volunteer for my informal data collection).

One of the biggest headaches, and arguably the most crucial aspect when sourcing research peptides, is understanding purity. You hear "HPLC" and "Mass Spec" thrown around a lot, often interchangeably, or with a vague sense that one is "better" than the other. But what do they *actually* tell me about the stuff I'm getting? Let me break it down from the perspective of someone who's seen hundreds of these reports.

The Illusion of the HPLC Report: What 98% Purity Really Means

When I first started, I saw "98% HPLC purity" and thought, "Great! That means 2% impurities." Simple, right? Oh, how naive I was. HPLC, or High-Performance Liquid Chromatography, is a workhorse in analytical chemistry. It separates compounds in a mixture based on their differing affinities for a stationary phase and a mobile phase. Think of it like a very sophisticated filter. The output is a chromatogram – a graph with peaks. The area under each peak corresponds to the amount of that compound.

So, if you see a big peak at the expected retention time for your peptide, and it's 98% of the total area, that *does* tell you that 98% of the stuff that *could be separated by that specific HPLC method* is your desired peptide.

Here's the rub:

1. **What *can't* it separate?** HPLC is great for separating things with different chemical properties. But what if you have isomers – compounds with the same chemical formula but different structures? What if you have something that co-elutes, meaning it comes out of the column at the same time as your peptide? HPLC can miss these. 2. **The "other 2%" is a black box.** That 2% impurity could be anything: residual solvents, starting materials, truncated sequences, or even other peptides. HPLC alone won't tell you *what* those impurities are, just that they're there. 3. **Methodology matters.** The solvent system, column type, flow rate, and detection wavelength all influence the results. A vendor could, theoretically, optimize their HPLC method to make their main peak look bigger and cleaner, while pushing impurities into the baseline or making them less detectable. I've seen some truly suspicious-looking chromatograms where the baseline is just a mess, but the main peak is pristine.

For me, an HPLC report is the *first filter*. It tells me if the vendor bothered to run a basic purity check. But it's far from the whole story.

Mass Spec: The "What Is It?" Detector

This is where Mass Spectrometry (MS) comes into play. If HPLC tells you *how much* of something is there, Mass Spec tells you *what* it is. MS works by ionizing molecules and then measuring their mass-to-charge ratio. Each peptide has a very specific molecular weight.

When I look at a Mass Spec report, I'm looking for a clear, strong signal at the expected molecular weight of the peptide. If I'm looking for BPC-157, which has a molecular weight of 1419.53 g/mol, I want to see a prominent peak around that value.

Here's why Mass Spec is critical:

* **Confirmation of Identity:** This is its primary power. It confirms that the main peak in your HPLC report is indeed the peptide you ordered. Without it, that 98% HPLC could be 98% of something else entirely. * **Identification of Impurities (sometimes):** If the impurities are also peptides or other ionizable compounds, MS can often identify their molecular weight. This is invaluable. If I see a significant peak at, say, 1200 g/mol for a BPC-157 sample, that immediately raises a red flag. It could be a truncated version or a byproduct. * **Detecting Adulteration:** While not foolproof, a wildly off-target MS report is a dead giveaway that you're not getting what you paid for.

So, for me, the combination of HPLC *and* Mass Spec is non-negotiable. HPLC tells me the *proportion* of the main component, and MS tells me the *identity* of that main component and gives clues about the impurities.

My "Reid's Purity Protocol" for Vetting Vendors

Given the wild west nature of this market – out of the 282 vendors I track, only 22% (61 of them) even publish named-lab COAs, and just 9 vendors clear a 4.5/5 average editorial rating – I developed a simple framework. I call it "Reid's Purity Protocol."

1. **Named-Lab COA:** Is the Certificate of Analysis from an independent, reputable third-party lab? Not an in-house report, and not a generic template with no lab name. This is step one. If they don't have this, I'm out. 2. **HPLC & MS Present:** Both reports must be included. An HPLC without an MS is like a car without an engine. 3. **Expected MW Match:** Does the Mass Spec show a prominent peak at the correct molecular weight for the peptide? 4. **Clean Chromatogram & Spectrum:** I'm looking for a relatively clean HPLC chromatogram with minimal extraneous peaks, and an MS spectrum that isn't a chaotic mess of signals. A little noise is expected, but not a rave party. 5. **Batch Specificity:** Is the COA specific to the *batch* I'm buying? A generic COA from two years ago for a different batch is useless.

If a vendor can't pass this simple five-step check, they don't make it onto my list of even potentially viable sources. You can find my current list of vetted sources on my /vendors page, and my top picks on the /best-peptide page.

Pushing Back: Why 99% Purity Isn't Always Better

Here's a counter-intuitive point I've learned. Common wisdom says "higher purity is always better." While generally true, blindly chasing 99%+ purity can be a fool's errand, especially for research-grade peptides.

Firstly, achieving ultra-high purity (99.5% and above) often requires more aggressive purification methods, which can sometimes degrade the peptide itself or introduce other unwanted byproducts in trace amounts. It's a diminishing returns game.

Secondly, and more importantly, what are the *impurities*? A 95% pure peptide with 5% known, inert, non-toxic impurities (like residual salts or a small amount of a harmless byproduct) might be preferable to a 98% pure peptide where the 2% impurity is an unknown, potentially toxic, or biologically active substance. HPLC alone won't tell you this. Mass Spec gives us clues, but often, the impurities are too low concentration to be fully characterized without more advanced techniques like NMR, which you'll almost never see on a standard COA.

My focus has shifted from obsessing over the exact percentage to understanding the *nature* of the impurities as best I can. A clean Mass Spec, even if the HPLC is 95-96%, often gives me more confidence than a 99% HPLC with a questionable MS.

In the end, it's about risk mitigation. We're dealing with research chemicals, and no amount of analysis will make it 100% safe. But understanding what these reports actually tell you, and what they *don't*, is crucial for making informed decisions.

*Disclaimer: I am not a medical professional. This article is for informational purposes only and is based on my personal research and experience. Peptides are research chemicals and are not approved by the FDA for human use. Do not interpret this as medical advice or instructions for human dosing. Always consult with a qualified healthcare professional before making any decisions about your health or treatment.*

Frequently asked questions

About the author

Marcus Reid: Marcus Reid spent a decade in software engineering before going deep into research on GLP-1 receptor agonists and peptide pharmacology. He reads the clinical literature, tracks his own biomarkers, and writes about what the data actually says. He is not a doctor; nothing here is medical advice.